GUADALAJARA, Mexico, June 27, 2019 (GLOBE NEWSWIRE) -- via NetworkWire –  CSSI

(Costas Inc.)  DBA Atlas  Nanotech has  entered an  accord with  Nano  Medical  S.R.O. of  the Czech  Republic. The  first  objective of  the accord  aims  to  establish distribution in new territories for both companies.

A most  important  aspect  of  the accord  is  each  company’s  experience  in  obtaining  government  approval  for   their  products  in  their   respective  territories. Atlas has successfully completed the submission of  documentation  and payment  for  two  unique  nanotechnology  products  through  the  Mexican  regulator COFEPRIS.  

Initially, Atlas plans to distribute Nano Medical S.R.O.’s products in  Mexico  and, eventually,  throughout  Latin America,  while  Nano Medical  S.R.O  will  distribute Atlas Nanotech’s products in Europe.

Atlas will begin by sending its Nano-Gauze and Nano-Membrane to be distributed in the EEC  (European Economic  Community), where  there are  over 70  million  diabetic patients. Nano Medical S.R.O. will, in turn, explore the  possibility  of  manufacturing  as  well  as  distributing  its  nanotechnology   products,  including “Zentiva,”  the company’s  patented nanotechnology  delivery  system  (women’s Viagra), in Mexico.

Atlas CEO Dr.  Julio Riestra  stated, “While  we are  in the  early stages  of  negotiations, the idea makes fiscal  and commercial sense for both  companies.  We will both be entering huge markets as experienced players with  established  pathways into distribution.”

Marcela Munzarova, CEO of  Nano Medical S.R.O. and  known as the “Nano  Lady,”  said this is  just the beginning,  and while both  companies will continue  to  work independently in the laboratory, the collaboration can lead to previously unthought-of breakthroughs in the field  of nano-medicine. Professor David  De  La Mora, chairman of Atlas, agreed adding that Nano Medical’s research in  the  field of nanofiber is very exciting and has huge potential.

About COSTAS Inc.

Costas Inc. has been trading under the  symbol CSSI since the year 2014.  With  the recent  acquisition  of  the  Guadalajara-based  nanomedicine  firm  Atlas  Nanotech, it now enters the  new dynamic market of nanotechnology  development  and manufacturing.


This press release and the statements of representatives of Costas, Inc.  (the  "Company") related  thereto  contain,  or may  contain,  among  other  things,  "forward-looking statements"  within the  meaning  of the  Private  Securities  Litigation Reform  Act  of 1995.  All  statements, other  than  statements  of  historical fact included  herein are  "forward-looking statements,"  including  any other  statements  of non-historical  information.  These  forward-looking  statements  are  subject   to  significant   known  and   unknown  risks   and  uncertainties  and  are  often  identified  by  the  use  of   forward-looking  terminology such as "guidance," "projects," "may," "could," "would," "should," "believes,"  "expects,"   "anticipates,"  "estimates,"   "intends,"   "plans,"  "ultimately" or similar  expressions. All  forward-looking statements  involve  material assumptions, risks and uncertainties, and the expectations  contained  in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the  date  of this  press  release.  The Company's  actual  results  (including,  without  limitation, Costas’  ability to  advance its  business, generate  revenue  and  profit and operate  as a public  company) could differ  materially from  those  stated or anticipated  in these forward-looking  statements as a  result of  a  variety of  factors, including  factors and  risks discussed  in the  periodic  reports  that  the  Company  files   with  OTC  Markets  (Pink  Sheets).   All  forward-looking statements attributable  to the Company  or persons acting  on  its behalf are  expressly qualified in  their entirety by  these factors.  The  Company undertakes no duty to  update these forward-looking statements  except  as required by law.




+52 33 1605 5418

Obtenido de: